Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Model No.: 111128-12-2
Brand: Mingya
Packaging: 25kg/Drum
Productivity: 5000mt One Year
Transportation: Ocean,Land
Place of Origin: China
Supply Ability: 1000kg
Certificate: state-owned enterprise
HS Code: 2916399090
Port: Shanghai,Qingdao
Payment Type: L/C,Paypal,Money Gram,Western Union
Incoterm: FOB,FCA
Stable supply, sufficient supply for experimental purposes, scientific research and development 2-(4-Bromomethyl)phenylpropionic acid CAS NO 111128-12-2
2-(4-Bromomethyl)phenylpropionic acid is one of the key Intermediates for the synthesis of Loxoprofen Sodium. Loxoprofen sodium was developed and marketed by Sankyo Pharmaceutical Co., Ltd. of Japan in 1986. It has been sold in Japan, South Korea, Europe and America, The country is listed, and the growth momentum is strong. my country has also started production and clinical application in recent years.
Name: | 2-(4-Bromomethyl)phenylpropionic acid |
Cas No: | CAS 111128-12-2 |
MF: | C10H11BrO2 |
Appearance: | White Powder |
purity: | >99% |
Brand Name: | Ming ya |
Delivery time: | Within 1-3 days payment |
Export Markets: | Global |
Other product categories:
3、Raw Drug
Our company is a professional company engaged in import and export trade, there are hundreds of products, product range is very rich, we always adhere to the most preferential price to provide the best quality products, more product details, welcome to contact us.
Product Categories : Raw Drug > Antihypertensive API
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.